These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22192091)

  • 41. Role of IL-15 in interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibody.
    Takada T; Ohashi K; Hayashi M; Asakawa K; Sakagami T; Kikuchi T; Sato S
    Respir Med; 2018 Aug; 141():7-13. PubMed ID: 30053975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
    Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies.
    Sato S; Kuwana M; Fujita T; Suzuki Y
    Mod Rheumatol; 2012 Aug; 22(4):625-9. PubMed ID: 22124544
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature.
    Chaisson NF; Paik J; Orbai AM; Casciola-Rosen L; Fiorentino D; Danoff S; Rosen A
    Medicine (Baltimore); 2012 Jul; 91(4):220-228. PubMed ID: 22732950
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk factors of interstitial lung diseases in clinically amyopathic dermatomyositis.
    Gan YZ; Zhang LH; Ma L; Sun F; Li YH; An Y; Li ZG; Ye H
    Chin Med J (Engl); 2020 Mar; 133(6):644-649. PubMed ID: 32049748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis.
    Kobayashi I; Okura Y; Yamada M; Kawamura N; Kuwana M; Ariga T
    J Pediatr; 2011 Apr; 158(4):675-7. PubMed ID: 21232756
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BATF2 balances the T cell-mediated immune response of CADM with an anti-MDA5 autoantibody.
    Li C; Liu M; Liu K; Li M; Liu Y; Li T; Wei Y; Long Y; He W; Shi X; Li Y; Zhang H
    Biochem Biophys Res Commun; 2021 Apr; 551():155-160. PubMed ID: 33740622
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
    Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.
    Tansley SL; Betteridge ZE; Gunawardena H; Jacques TS; Owens CM; Pilkington C; Arnold K; Yasin S; Moraitis E; Wedderburn LR; McHugh NJ;
    Arthritis Res Ther; 2014 Jul; 16(4):R138. PubMed ID: 24989778
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Autoantibodies against TIF-1-γ and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): clinical significance and diagnostic utility.
    Cuesta-Mateos C; Colom-Fernández B; Portero-Sainz I; Tejedor R; García-García C; Concha-Garzón MJ; De las Heras-Alonso ME; Martínez MA; Juarez C; Muñoz-Calleja C
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):482-9. PubMed ID: 25065441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
    Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An Atypical Clinical Course of Anti-MDA5 Antibody-positive Interstitial Lung Disease in a Patient with Three Deteriorations in 9 years.
    Sato Y; Otsuka K; Tamai K; Ono Y; Hamaguchi Y; Tomii K
    Intern Med; 2017; 56(3):341-346. PubMed ID: 28154280
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Double anti-PL-7 and anti-MDA-5 positive Amyopathic Dermatomyositis with rapidly progressive interstitial lung disease in a Hispanic patient.
    Li ZY; Gill E; Mo F; Reyes C
    BMC Pulm Med; 2020 Aug; 20(1):220. PubMed ID: 32799827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
    Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
    Sato S; Kuwana M; Fujita T; Suzuki Y
    Mod Rheumatol; 2013 May; 23(3):496-502. PubMed ID: 22644102
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.
    Peng Y; Zhang S; Zhao Y; Liu Y; Yan B
    Clin Rheumatol; 2018 Jan; 37(1):107-115. PubMed ID: 28842784
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease.
    Nishina N; Sato S; Masui K; Gono T; Kuwana M
    RMD Open; 2020 Jun; 6(2):. PubMed ID: 32506053
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.
    Gerami P; Schope JM; McDonald L; Walling HW; Sontheimer RD
    J Am Acad Dermatol; 2006 Apr; 54(4):597-613. PubMed ID: 16546580
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.
    Asakawa K; Yoshizawa K; Aoki A; Kimura Y; Tanaka T; Ohashi K; Hayashi M; Kikuchi T; Sato S; Takada T
    Clin Rheumatol; 2020 Jul; 39(7):2171-2178. PubMed ID: 32056068
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
    Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.